Articles On Alcidion Group (ASX:ALC)

The Alcidion Group Ltd (ASX: ALC) share price is on the move today as shareholders digest the company’s fourth-quarter performance. Shares in the healthcare software provider are 9.1% higher this morning, trading hands at 12 cents apiece....

Clinical validation study confirms efficacy of INOVIQ’s SubB2M/CA15-3 test for breast cancer Ramsay releases several announcements this week including possible sale of joint Asian venture Mach 7 expects significant cash collections in Q4...

New research identifies Alcidion Group is attaining scale and becoming profitable at an opportune time for healthcare technology demand. -Alcidion Group’s expanded offering in a time of industry demand-Proven business model is scaling and b...

An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now...

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

Neurotech will extend its Phase 1/2 trial after ethics approval Alcidion makes further inroads into UK’s public hospitals   Neurotech to extend Phase 1/2 trial after ethics approval Paediatric neurological disorders specialist, Neurotech...

Wall Street was closed for Memorial Day, European shares were slightly down Beware of “downside correction” in the US market, expert says Rampant short-selling is putting pressure on the oil markets   Wall Street was closed for Memorial D...

It remains a nerve-wracking time for investors in small-cap ASX shares. Inflation is still flying high, interest rates are still heading up, and there is still no certainty as to whether the world will avoid a recession. But, according to...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

The tech heavy Nasdaq has officially entered a bull market How long do bulls market usually last? And what will the Nasdaq rally mean for ASX tech stocks?   Well, what do you know? Far from being in a crash-landing recession after the nea...

With so many shares to choose from on the ASX, it can be hard to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you. Three top ASX shares that leading brokers have named as b...

A deep valuation rift has emerged between the larger established tech stocks and the loss-making minnows, with fears that many of the small ‘uns simply will run out of cash in a hostile fund raising climate. Of course the collapse of Silico...

Alcidion increased sales significantly in the first half Cogstate sounds warning on outlook Probiotic had a super half   Most biotech firms on the ASX are clinical stage companies, meaning they are still trying to prove that their drugs a...

A $1 million portfolio might seem like a far-off dream unless you start by investing an already large sum of money. Though, picking ASX shares with the potential for returns greater than 2,000% over the long term makes this dream much more...

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

There have been countless quarterly updates released on Monday. Some have been received well by investors, others less so. Three that haven’t gone down particularly well with investors are summarised below. Here’s why these ASX All Ord...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

Alcidion (ALC) has penned an extension to its agreement with Leidos Australia for the additional delivery of a management system to support healthcare services across the Australian Defence Force (ADF)The contract extension is expected to h...

Highlights The ASX 200 benchmark index closed in the green today (December 1), gaining 65.50 points or 0.90% to end at 7,349.70 points. Over the last five days, the index has gained 1.49%, but is down 1.27% for the last year to date....

Alcidion (ALC) signs a three-year agreement with the University Hospital Southampton NHS Foundation Trust (UHS) to implement its Miya Precision IT platformThe $2.8 million contract will see the company deliver a modern, modular electronic p...

Kazia’s positive results published in a Journal Cochlear’s proposed acquisition raised concerns with the ACCC Aldion signs multi-million dollar deal Kazia’s positive results get published Oncology biotech Kazia Therapeutics (ASX:KZA) ann...

According to Oxford Languages, ‘motley’ means “incongruously varied in appearance or character”. But in relation to our Foolish writers, it means they vary greatly with regard to age, risk tolerance, and stage of life as well as in...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

We take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks from 2021 have gained since listing We also look at the best and worst performing ASX stocks over the past month   There were 191 ASX IPOs in...

It’s been a rough year for investors of small-cap ASX shares. “All types of investing require nerve and courage. But perhaps none more so than small-cap stocks,” said Ophir analysts in a memo to investors this month. “When an economic down...

The Dubber Corp Ltd (ASX: DUB) share price will emerge from the ASX suspension on Monday. I’m guessing the Dubber share price will be punished. For context, I wrote last week why Dubber shares were suspended. I have no dog in this fight — f...

Claude Walker is the founder of A Rich Life and a small-cap investing expert. Claude joins Owen Rask on The Australian Investors Podcast to help us understand where we might be in the market cycle, and the duo identifies two of their favour...

The Australian Investors Podcast welcomes back Claude Walker, founder of A Rich Life, to talk about 5 companies that caught his eye during ASX Reporting Season, including Objective Corporation Ltd (ASX: OCL), PWR Holdings (ASX: PWH) and mor...

Dubber Corp Ltd (ASX: DUB), Alcidion Group Ltd (ASX: ALC), Fortescue Metals Group Ltd (ASX: FMG) and Wesfarmers Ltd (ASX: WES) feature on this week’s Australian Investors Podcast. Drew Meredith, CFP and Owen Rask are back on The Australian...

This week, we bid farewell to winter… and another tumultuous ASX earnings season. So now, looking ahead to the brighter days of spring, hopefully the stock market can also deliver some healthy new growth. Armed with a barrow full of inf...

The All Ordinaries Index (ASX: XAO) is in the green so far today. At the time of writing, it’s 0.52% higher at 7,231 points. Earnings season has been a busy one with plenty of mixed results. Here are three ASX All Ordinaries standouts that...

An additional news report on the recommendation, valuation, forecast and opinion changes for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Au...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is fighting hard to stay in positive territory. At the time of writing, the benchmark index is up a fraction to 6,810.2 points. Four ASX shares that are climbing more than most tod...

The Alcidion Group Ltd (ASX: ALC) share price has been a strong performer on Wednesday. In afternoon trade, the healthcare technology company’s shares are up over 18% to 16 cents. This follows the release of Alcidion’s unaudited fourth...

Digital healthcare company Alcidion (ALC) achieves record quarterly cash receipts of $14 million for the June quarter Total cash receipts for FY22 came to $41.4 million, a 29 per cent increase on the prior year, resulting in positive opera...

Ask A Fund Manager The Motley Fool chats with the best in the industry so that you can get an insight into how the professionals think. In this edition, Cyan Investment Management portfolio manager Dean Fergie nominates a bargain ASX share...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

Fears of rising interest rates have really taken their toll on growth and small-cap ASX shares. That’s because smaller, rapidly expanding businesses are typically the ones who have taken on debt to fuel their growth. And when a company bor...

This year has been a rough ride for most ASX shares, but small-cap companies have suffered more than their larger cousins. The Cyan C3G Fund, which specialises in small-cap stocks, has felt the pain as much as any retail investor. Portfoli...

Dean Fergie, is the co-founder of Melbourne-based Cyan Investment, where his 25 years in funds management across all major asset classes is poured into one single fund. Dean has absolutely no intention of being all things to all people. “We...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

In this episode of The Australian Investors Podcast, Owen Rask is joined by 7Investing’s Dr Anirban Mahanti to talk markets, the economy, how to value tech stocks and more. Stocks mentioned in the podcast include: Target Corporation (NYSE...

An additional news report on the recommendation, valuation, forecast and opinion changes for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Au...

Healthcare and life sciences expert Scott Power – a senior analyst with Morgans Financial for 24 years – on what the movers and shakers have been doing in health and which ASX health stocks make Scott’s Powerplays. Are you the cuddly type?...

If you’re wanting to invest in the small side of the Australian share market, then the three small caps listed below could be worth a closer look. Here’s why these small cap ASX shares could be worth adding to your watchlist: Adore Beauty...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

Highlights The benchmark index ASX200 was down 0.817% at 7258.200 points at 3:22 PM AEST on Wednesday (27 April 2022). The S&P/ASX 200 Health Care Index (ASX:XHJ) was 1.380% lower at 40598.200 points during the intraday trading ses...